In honor of the 15-year anniversary of the founding of the Clinical Data Interchange Standards Consortium (CDISC) and the recently approved CDISC status as a 501(c)(3) charitable foundation, the Annual Report for year 2011 has been released and is available for download on the CDISC website.
In honor of the 15 year anniversary of the founding of the Clinical Data Interchange Standards Consortium (CDISC) and the recently approved CDISC status as a 501(c)(3) charitable foundation, the Annual Report for year 2011 has been released and is available for download on the CDISC website.
Key successes CDISC has had over the past 15 years are displayed graphically in a two-page timeline detailing major achievements since the organization’s founding in 1997. The report includes the mission and vision of CDISC, milestones for year 2011, and information about CDISC-certified education. Trends in CDISC membership and current leadership information are also detailed. Fascinating insight is given in the Annual Report to the rapid growth and productivity of CDISC since its beginnings as a strictly volunteer organization.
Readers also have the opportunity to get a closer look at where CDISC is heading over the next three years, through the inclusion of the CDISC Strategic Goals for 2012-15. The CDISC Board of Directors has been focused on delineating this new set of Strategic Goals since its Annual Meeting in 2011, and these were officially launched in January 2012. In summary, these five goals focus on: 1) supporting data aggregation and secondary use of research data; 2) enabling interoperability between clinical care and clinical research; 3) developing CDISC SHARE (shared health and research electronic library); 4) expediting the development of new therapeutic area standards to augment the CDISC foundational standards to support the needs of researchers and the FDA; and, 5) leveraging our global, nonprofit, vendor neutral, independent status to forge productive collaborations with and ensure value for key stakeholder communities.
“CDISC prides itself on doing its utmost to provide understandable, transparent information about the operational activities of the organization,” stated Dr. Rebecca Kush, CDISC President and CEO. “This first public Annual Report is a major accomplishment for CDISC, displaying the incredible effort and dedication of a multitude of members, volunteers and CDISC staff, who have worked around the world for 15 years to make CDISC what it is today-the common language for clinical research.”
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.